Volume | 7,230 |
|
|||||
News | - | ||||||
Day High | 5.88 | Low High |
|||||
Day Low | 5.3112 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.59 | 5.3112 | 5.88 | 5.35 | 5.61 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
170 | 7,230 | $ 5.54 | $ 40,048 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 78 | $ 5.41 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
19.99M | 3.74M | - | 583k | -14.29M | -3.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.05 | 6.23 | 5.3112 | 5.82 | 4,092 | -0.70 | -11.57% |
1 Month | 6.13 | 6.80 | 5.3112 | 6.24 | 9,078 | -0.78 | -12.72% |
3 Months | 5.30 | 8.8465 | 4.8201 | 6.63 | 35,185 | 0.05 | 0.94% |
6 Months | 5.08 | 8.8465 | 3.35 | 6.09 | 22,288 | 0.27 | 5.31% |
1 Year | 4.13 | 8.8465 | 2.78 | 4.69 | 26,108 | 1.22 | 29.54% |
3 Years | 93.20 | 156.00 | 2.78 | 80.06 | 624,402 | -87.85 | -94.26% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.72 | 564,272 | -303.85 | -98.27% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |